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Abstract
The combined use of in vitro (19F-NMR) and in silico (molecular docking) procedures dem-
onstrates the affinity of a number of human calycins (lipid-binding proteins from ileum, liver,
heart, adipose tissue and epidermis, and retinol-binding protein from intestine) for different
drugs (mainly steroids and vastatins). Comparative evaluations on the complexes outline
some of the features relevant for interaction (non-polar character of the drugs; amino acids
and water molecules in the protein calyx most often involved in binding). Dissociation con-
stants (Ki) for drugs typically lie in the same range as Ki for natural ligands; in most instances
(different proteins and docking conditions), vastatins are the strongest interactors, with ator-
vastatin ranking top in half of the cases. The affinity of some calycins for some of the vasta-
tins is in the order of magnitude of the drug Cmax after systemic administration in humans.
The possible biological implications of this feature are discussed in connection with drug
delivery parameters (route of administration, binding to carrier proteins, distribution to, and
accumulation in, human tissues).
Introduction
Carrier proteins in plasma are able to bind a number of exogenous compounds—including
drugs—with close to distant resemblance to the endogenous ligands [1, 2]. This interaction,
which mainly involves albumin [3] and α1-acid glycoprotein/orosomucoid [4], features low
selectivity but high capacity (large amounts of heterogeneous substances being bound by these
abundant plasma proteins), and greatly impacts on the pharmacokinetic and pharmacody-
namic profile of the therapeutic agents. Plasma protein level variations with age (with the
extreme case of the rapidly changing concentrations in newborns) [5] and between sexes [6, 7]
do influence drug distribution. Even more so do the variations induced by disease, with
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albumin behaving as a negative and α1-acid glycoprotein/orosomucoid as a positive acute
phase reactant [8]. Differences in the binding sites across species [9, 10] are confounding fac-
tors in translational medicine.
As definitely proven for albumin [11], drugs interact with the same binding sites as the
endogenous ligands (for h-albumin, Sudlow’s site 1 in subdomain IIA and Sudlow’s site 2 in
subdomain IIIA [12]). This is the basis for competition/displacement between endogenous
and/or exogenous compounds, in health and disease (for instance, albumin vs fatty acids [13,
14] and uremic toxins [13, 15], and α1-acid glycoprotein/orosomucoid vs imatinib and erythro-
mycin [16]). This is also the basis for the quest of procedures for the in silico estimation of drug
binding to plasma proteins, and notably to albumin, as such an information is expected to con-
tribute to the lead optimization process in early drug discovery [17, 18]. A number of albumin-
based drug delivery systems are being developed [19, 20]; while some involve chemical cou-
pling (from pro-drugs and peptide derivatives covalently bound to albumin to albumin fusion
proteins), some only call for physical interaction with the binding site (high-affinity drugs are
loaded into albumin nanoparticles [21], low-affinity drugs are engineered as to bind to albumin
in order to extend their half-life [22]).
Interaction with exogenous compounds structurally related to the endogenous ligands may
be expected as well for a number of proteins in cells whose molecular function may be
described with such GO terms as binding and/or transporter (http://geneontology.org). Many
of them belong to the calycin superfamily; these share a remarkable structural signature (a
repeated +1 topology β-barrel) in spite of limited regions of sequence similarity [23–25] and
are able to accommodate into their calyx a variety of small hydrophobic metabolites (fatty acid,
steroids, bilins, retinoids). Interaction of calycins with drugs has been considered in various
perspectives. The calyx architecture offers several opportunities for therapeutic applications:
the most radical involves the engineering of the natural proteins to produce anticalins, anti-
body mimetics devised to bind specific ligands, including drugs for targeted delivery [26–29].
In a simpler option, binding to a wild-type calycin (β-lactoglobulin) preserves acid-labile drugs
from exposure to the pH lows of gastric secretion and opens to their oral administration in a
protein vehicle [30–32].
In contrast with the host of data available about the interaction between drugs and circulat-
ing proteins, fewer studies have been devoted to the role of intracellular proteins, which is the
aim of this report.
Materials and Methods
c-FABPL purification
Fatty acid-binding protein from G. gallus liver (entry P80226 in http://www.uniprot.org/ data-
base; short name = c-FABPL) was purified from chicken liver as in [33, 34]. The row animal
material was obtained fresh, in batches of some kilograms, from the food market (AIA—Agric-
ola Italiana Alimentare S.p.A., San Martino Buon Albergo (VR), Italy). The EC regulations to
which the producers had to comply in their proceedings are: No 853/2004 (laying down spe-
cific hygiene rules for food of animal origin), No 854/2004 (laying down specific rules for the
organisation of official controls on products of animal origin intended for human consump-
tion) and No 1099/2009 (on the protection of animals at the time of killing). As involving
food/feed items, no IACUC or ethics committee approval was required for our laboratory
procedures.
After delipidation (via Lipidex treatment), aliquots of protein solutions in phosphate buffer
(10 mM, pH 7.34) were concentrated by ultrafiltration, typically to ca. 1 mM as estimated by
UV measurements (ε280 = 9423 M
-1 cm-1).
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Ligands
The ligands for in vitro and in silico tests are listed in Table 1. Those used in NMR experiments
were purchased from Sigma Aldrich and used as such. Fluvastatin, a generous gift from Novar-
tis, was carefully desiccated under vacuum and stored under nitrogen in sealed vials.
19F-NMR spectroscopy
Stock solutions of poorly water-soluble ligands were prepared by dissolving weighted amounts
in freshly distilled organic solvents: CH2Cl2 for norfloxacin (ca. 10 mM), flurbiprofen (ca. 15
mM), sulindac (ca. 10 mM), 5-fluorosalicylic acid (ca. 27 mM); MeOH for dexamethasone (ca.
10 mM); diethylic ether for 2-fluoropalmitate (ca. 5.5 mM). Volumes of these solutions appro-
priate to result in varying stoichiometric ratios to c-FABPL were transferred in 5 mmNMR
tubes and the solvent was slowly evaporated in a dry nitrogen stream. Stock solutions of fluvas-
tatin sodium salt (ca. 10 mM) and dexamethsone-21-phosphate disodium salt (ca. 35 mM)
were prepared in 10 mM phosphate buffer pH 7.4 (PBS). c-FABPL/ligand binding stoichiome-
try was established through stepwise interaction experiments. Protein solutions were sequen-
tially incubated with a defined stoichiometric amount (typically 0.5 eq) of the ligand and the
interaction process was monitored through the acquisition of a series of 19F spectra. For the
poorly soluble ligands, parallel control experiments were performed in the absence of c-
FABPL, by monitoring their possible dissolution in PBS through the acquisition of 19F spectra.
For all the other experiments, c-FABPL solutions were previously incubated with the appro-
priate amount of ligand in the NMR tube for at least 12 h in a thermostatic bath at 298 K. Typi-
cally, {1H}19F spectra were acquired at 298 K on a Bruker DRX300 equipped with a QNP probe
Table 1. Data on the test ligands.
# name log P activity
1 norﬂoxacin -1.13 synthetic antibacterial
2 dexa-methasone phosphate -0.32 synthetic glucocorticoid
3 5-ﬂuoro-salicylate -0.11 salicylate = active metabolite of aspirin, a nonsteroidal anti-inﬂammatory
4 pravastatin 1.11 synthetic antilipidemic
5 dexa-methasone 1.90 synthetic glucocorticoid
6 beta-methasone 1.90 synthetic glucocorticoid
7 cholate 2.11 bile acid
8 R-ﬂurbiprofen 2.35 nonsteroidal anti-inﬂammatory
9 S-ﬂurbiprofen 2.35 nonsteroidal anti-inﬂammatory
10 ﬂuocinolone acetonide 2.37 synthetic glucocorticoid
11 simvastatin 2.77 synthetic antilipidemic
12 ﬂuocinolone acetonide acetate 2.94 synthetic glucocorticoid
13 sulindac 3.03 nonsteroidal anti-inﬂammatory
14 ﬂuvastatin 3.39 synthetic antilipidemic
15 cerivastatin 3.81 synthetic antilipidemic
16 R-ﬂuoro-palmitate 4.17 palmitate = medium-chain fatty acid
17 S-ﬂuoro-palmitate 4.17 palmitate = medium-chain fatty acid
18 palmitate 4.22 medium-chain fatty acid
19 atorvastatin 5.25 synthetic antilipidemic
20 cholesterol 7.39 membrane lipid
Natural and synthetic compounds are listed in order of increasing partition coefﬁcient (logP)
doi:10.1371/journal.pone.0132096.t001
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collecting 240–400 transients of 8 K data points over a spectral width of 14,000 Hz. The stan-
dard inversion recovery pulse sequence was used for the longitudinal relaxation time (T1) mea-
surements employing 10–12 variable delays (ranging from 1 ms to 25.0 s) for each experiment
and allowing for complete relaxation a delay at least five times the estimated relaxation time.
T1 values were obtained from a non-linear three parameters fit of the experimental data. The
heteronuclear Overhauser enhancement (heteronuclear n.O.e.) was estimated according to the
following relationship: η = (Id − I0)/I0, where Id and I0 are the integrated intensities of
19F sig-
nals in spectra acquired with and without proton decoupling during the relaxation time.
Competition experiments
Solutions of selected c-FABPL complexes in PBS were treated with stoichiometric or stepwise
increasing amounts of putative competitive ligands. Appropriate volumes of stock solutions of
the test ligands were added directly to the c-FABPL complex solutions (when the ligand was
buffer soluble) while poorly soluble species were previously deposited through evaporation
into an NMR tube in which the c-FABPL complex solution was then transferred. Reference
19F-NMR data were recorded before and after overnight incubation at 298 K. In some cases 19F
spectra were also recorded during the incubation step.
Molecular docking
All computational procedures were performed with modules and programs of the MOE suite
(Molecular Operating Environment, release 2013.08, by Chemical Computing Group Inc.,
Montreal, QC, Canada).
“A consensus water molecule is defined as one that is within 1 Å of another water molecule
seen in at least one other structure” [35]. To identify consensus water, the 11 structures of the
selected calycins that had been resolved by X-ray crystallography (Table 2, notes) were super-
posed after alignment of the protein sequences with T-Coffee (Tree-based Consistency Objec-
tive Function For alignment Evaluation http://www.ebi.ac.uk/Tools/msa/tcoffee/) (alignment
data in S1 Fig). The identification procedure (a feature of the 2014 release of the suite,
described in file:///Applications/moe2013/html/proteins/procore.htm#WaterConsensus) was
repeated on the protein structures while changing the water site contribution parameter. A
Table 2. Data on the test calycin structuresa.
# species organ short name UniProtb RCSBc ligand RCSBc ligand
I G. gallus liver c-FABPL P80226 1TVQd apo form 1TW4d 2x cholate
II H. sapiens ileum gastrotropin P51161 1O1Ue apo form 1O1Ve 1x taurocholate
III H. sapiens liver h-FABPL P07148 3STNd apo form 3STKd 2x palmitate
IV H. sapiens heart h-FABPH P05413 1G5Wd apo form 2HMBd 1x palmitate
V H. sapiens adipose tissue h-FABPA P15090 3RZYd apo form 2HNXd 1x palmitate
VI H. sapiens epidermis h-FABPE Q01469 4LKPd apo form 1B56d 1x palmitate
VII H. sapiens small intestine h-RETI P50120 2RCQd apo form 2RCTd 1x retinol
a proteins are listed in order of decreasing similarity to c-FABPL
b http://www.uniprot.org/
c http://www.rcsb.org/pdb/home/home.do
d structure resolved by X-ray crystallography
e structure resolved by NMR
doi:10.1371/journal.pone.0132096.t002
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value of 6 with B-factor added to RMSD was set and produced the output in S1 Table, corre-
sponding to the constellation of water molecules shown in Fig 1.
The number of consensus water molecules varies between 1 and 5, depending on the protein
and on the form of the protein being apo or holo. Non-consensus water molecules were (manu-
ally) removed from the pdb file of the holo form for each of the target proteins, and the protein
structures were protonated (3D protonation).
The database of ligands in Table 1 was docked under default conditions to the resulting pro-
tein structures, first in the presence of consensus water then in its absence, using the Amber12:
EHT force field (docking protocol = rigid receptor, receptor = receptor+solvent, or receptor
atoms, site = ligand atoms, placement = triangle matcher, rescoring-1 = London dG, refinement
= forcefield, and rescoring-2 = GBVI/WSA); only docking in the absence of water was feasible
with gastrotropin, whose structure has been resolved by NMR. In all instances 1:1 protein/
ligand complexes were simulated.
In detail, rigid molecular docking was carried out on the holo protein structures targeting
the site of the crystallographic ligands. Poses were generated by superposition of ligand atom
triplets and triplets of receptor site points, the latter alpha sphere centers, i.e. locations of tight
packing. The 30 top-scoring non-duplicate poses were subjected to an energy minimization
procedure and then re-scored according to the GBVI/WSA dG scoring function, which com-
putes an approximate value for binding free energy.
Fig 1. Consensus water for the 11 calycin structures in Table 2 resolved by X-ray crystallography,
displayed against a line rendering of the backbone of the same proteins.Water molecules rendered in
red map inside, in blue outside the calyx.
doi:10.1371/journal.pone.0132096.g001
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To validate the accuracy of the above protocol in reproducing ligand binding orientation
with the specific receptors and under the specific conditions used in the present investigation,
we searched in our experimental set for a protein to have been crystallized both in the presence
of a natural ligand and of a synthetic drug. For h-FABPA, in the RCSB Protein Data Bank
(http://www.rcsb.org/pdb/home/home.do) we found 2HNX, which contains palmitate (see
Table 2), and 6P6G, which contains ibuprofen. We docked both ligands back to the cognate X-
ray structure: the top scoring rmsd between computed and experimental position of ligand
atoms was 0.84 Å when redocking palmitate to 2HNX (S2 Fig, panel A), 0.37 Å when redocking
ibuprofen to 6P6G (panel B). Docking ibuprofen to 2HNX with consensus water yielded a top
scoring pose completely overlapping with the crystallographic ligand when the docked com-
plex was superposed to 6P6G (panel C).
The interactions between ligands and proteins were summarized in the format of Protein
Ligand Interaction Fingerprints (PLIF) on the basis of docking data both in the presence and in
the absence of consensus water.
in silico dissociation constant determination
For each ligand, the top-scoring pose (according to the GBVI/WSA dG scoring parameter) was
used for computing affinity. The complexes were refined through the use of a set of specific
MOE molecular mechanics procedures aimed at the relaxation of ligands in the receptor bind-
ing site. During these steps, protein side chain atoms and ligand atoms were left free to move.
The dissociation constant (Ki) was then computed through the binding free energy, as esti-
mated via the GBVI/WSA dG scoring function, according to the following equation: Ki = e
ΔG/
RT, where R represents the gas constant and T the absolute temperature (300 K).
Results
Our group has first purified and extensively characterized structure and function of one intra-
cellular calycin, c-FABPL; technical approaches included X-ray crystallography, 1H-NMR,
13C-NMR, molecular docking and molecular dynamics [33, 34, 36–40].
Further working on this protein, during the present investigation we carried out in vitro
interaction tests between purified c-FABPL and a number of fluorine-containing compounds
with unlike chemical structure, as shown in Table 1; selection criteria favored drugs and drug
analogs with diverse pharmacological activity, differing in molecular mass and partition coeffi-
cient. Binding was assessed by evaluating the 19F-NMR spectra of protein-drug mixtures. In sil-
ico simulations of the interaction between c-FABPL and the test ligands were performed in
parallel and compared with the in vitro findings. The same compounds were then docked to
selected human intracellular calycins to evaluate the likelihood of in vivo protein/drug
interactions.
in vitro data: c-FABPL interactions
The high sensitivity of 19F heteronuclear NMR proves very useful for assessing ligand binding,
mainly through the measurement of the longitudinal relaxation time (T1) and of the hetero-
nuclear Overhauser effect (heteronuclear n.O.e.). Indeed, sometimes only small changes are
observed in the chemical shift of the ligand reporter nuclei after protein/ligand interaction.
Instead, the relaxation parameters are extremely sensitive to the changes of the motional
regime that occur upon binding of the ligand to a macromolecule. The increase of the correla-
tion time results in a significant decrease of T1 and n.O.e., the latter eventually reaching nega-
tive values (for 19F, ηmax = -1.04 in the slow motion regime vs ηmax = + 0.54 in the extreme
narrowing conditions).
Lipid-Binding Protein – Drug Interactions
PLOS ONE | DOI:10.1371/journal.pone.0132096 July 13, 2015 6 / 22
As shown in Table 3, the relaxation parameters evaluated after the incubation with c-
FABPL, in particular the negative n.O.e. values, point to the occurrence of binding between the
protein and all the test ligands.
For most of the ligands a single signal is observed even in the presence of 2 equivalents of
drug but the integrated intensity of this resonance does not support the binding of 2 ligand
molecules. Fig 2 shows, as an example, the behavior of dexamethasone. Its buffer solubility
(0.25 mM in PBS with 10% DMSO, https://www.caymanchem.com/pdfs/11015.pdf) is lower
than the concentration required to saturate a 1 mM solution of the protein. However, the inte-
grated intensity of the signal after the first step of the interaction (0.5/1 ratio) is greater than for
the same amount of dexamethasone in the absence of the protein; the intensity further
increases after the second step of the interaction. This indicates that c-FABPL increases dexa-
methasone solubility through formation of a complex (1/1 ratio). When the overall amount of
the drug exceeds 1 equivalent, only a small increase of the intensity of the signal is observed,
compatible with the poor solubility of the drug in buffer. With ligand exceeding 1/1 ratio, the
relaxation time becomes longer and the n.O.e. less negative (Table 3). These findings support
the notion that, beyond 1 eq, the single signal results from the fast exchange between the
(small) number of dexamethasone molecules free in solution and those bound to the protein.
Instead, in the case of fluvastatin, flurbiprofen and 2-fluoropalmitate, 19F-NMR spectra (Fig
3 and S3 Fig) show two resonances; both their intensities increase when the protein is treated
with more than 1 eq of drug (Fig 3). This latter evidence rules out the hypothesis that the two
signals arise from two different conformations of each ligand in a single binding site. Previous
X-ray [38] and NMR studies [41] have shown that c-FABPL can indeed accommodate in its
Table 3. 19F-NMR data on protein-ligand complexes.
# ligand δ free δ bound T1 free (s) T1 bound (s) η free η bound ligand/protein ratio
1 norﬂoxacin -124.72 -124.55 0.86 0.27 0.22 -0.18
2 dexamethasone phosphate -164.43 -164.27 0.74 0.39 0.34 -0.41
3 5F-salicylate -125.08 -125.24 4.88 1.03 0.24 -0.58
5 dexamethasone -164.20 -163.78 0.81 0.28 0.41 0.5/1
-163.90 0.32 -0.77 1/1
-163.97 0.36 1.5/1
-163.98 0.40 -0.46 2/1
8–9 ﬂurbiprofen -119.24 -118.90 2.0 0.54 0.19 -0.66 1/1
-119.09 0.52 -0.57
-119.08 0.67 -0.29 2/1
-119.15 0.68 -0.57
10 ﬂuocinolone acetonide -186.45 -186.50 0.74 0.27 0.32 -0.84
-165.12 -165.30 0.96 0.33 0.19 -0.84
13 sulindac -113.65 -113.50 1.17 0.59 0.23 -0.46
14 ﬂuvastatin -116.43 -116.31 2.03 0.26 -0.74 0.5/1
-116.41 -0.7
-116.32 -0.54 1/1
-116.40 -0.71
-116.40 0.55 -0.59 2/1
16–17 2F-palmitate -194.14a -180.94 2.47a 0.24 0.29a -0.54
-181.10 0.23 -0.58
a free ligand data in CDCl3
doi:10.1371/journal.pone.0132096.t003
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Fig 2. 19F-NMR spectra recorded after the interaction of c-FABPLwith increasing amounts of
dexamethasone, from 0.5 to 2 equivalents (traces a-d). The spectrum of the ligand in the absence of the
protein is reported in trace e. Operating conditions: phosphate buffer pH 7.4, 7 T, 298 K.
doi:10.1371/journal.pone.0132096.g002
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cavity two molecules of bile acids. For both the drug/protein complexes, the two resonances
have different linewidths that, as estimated through deconvolution, change on increasing the
overall amount of drug: for fluvastatin 25.4 and 20.9 Hz, 25.8 and 15.1 Hz, 23.3 Hz for 0.5/1, 1/
1 and 2/1 ligand/protein ratios, respectively; for flurbiprofen 26.5 and 13.3Hz, 16.4 and 8.8 Hz
in the case of 1/1 and 2/1 ligand/protein ratios, respectively. Also, on increasing the overall
amount of drug, the chemical shifts of both signals change and (when measurable) the n.O.e.
of the broader, low-field resonance become less negative (Fig 3 and Table 3). These data suggest
that two binding sites are involved, which enable different mobility for the ligand molecules: in
c-FABPL the binding to the site responsible for the low-field resonance allows exchange
between protein-bound ligand and free molecules in solution. In [41], 15N solution studies
reported a similar behavior for glycocholate: the ligand in one of the two binding sites (dubbed
“superficial site”) was found to exchange with free ligand in solution (vide infra). The low-field
resonances could therefore be attributed to drug molecules bound to the superficial site of c-
FABPL. Moreover the shifts (in opposite directions) of the high field signals of fluvastatin and
flurbiprofen complexes, observed on increasing the overall amount of drug, suggest also the
possible occurrence of other dynamic processes involving the second site, namely exchange
with the free ligand (for flurbiprofen) or exchange between the two bound ligands (for
fluvastatin).
We then performed competition experiments between selected c-FABPL/drug complexes
and cholate or/and glycocholate, two of the bile acids known to be physiological ligands for c-
FABPL, using natural abundance or selectively 13C-enriched bile acid samples. Preliminary
interaction experiments performed on the apo protein using selectively 13C-enriched ligands
confirmed the presence of two different binding sites. The titration indicates two sites of com-
parable affinity for cholate, and of different affinity for glycocholate (Fig 4). For the latter, the
broad linewidth of the low-field signal (trace e) is in line with the known occurrence of
exchange with free ligand in solution [41].
Fig 3. 19F-NMR spectra recorded after the interaction of c-FABPLwith increasing amounts of fluvastatin (from 0.5 to 2 equivalents; panel A traces
a-c) and flurbiprofen (1 and 2 equivalents, panel B, traces e,f). The spectra of the drugs in the absence of the protein are shown in traces d (fluvastatin)
and g (flurbiprofen). Operating conditions: phosphate buffer pH 7.4, 7 T, 298 K.
doi:10.1371/journal.pone.0132096.g003
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Upon addition of cholate to the complex c-FABPL/dexamethasone, the drug was quantita-
tively removed from the protein at a 1:1 ratio (Fig 5), indicating a lower affinity for the drug
than for cholate. Instead, in the case of the complex c-FABPL/2-fluoropalmitate (Fig 6), only
using a tenfold excess of cholate the ligand was completely removed from the protein, indicat-
ing an affinity higher for the palmitate derivative than for cholate. 2-fluoropalmitate is water-
insoluble, hence its 19F signal disappeared at first (traces c-d: the ligand displaced by cholate
did precipitate) but, when cholate concentration was increased above cmc, the long-chain fatty
acid was dispersed in the bile acid micelles and its signal became again visible (traces e-f).
Symmetric competition experiments between fluvastatin and cholate (that is, c-FABPL/flu-
vastatin complex treated with increasing amounts of cholate, and viceversa) proved that the
two ligands bind to c-FABPL with comparable affinity. Indeed, even using an eightfold excess
of the competing ligand neither the relaxation parameters nor the position of the signals did
return to the values associated with the free molecule. A similar behavior was observed with
glycocholate and flurbiprofen (data not shown).
in silico data: c-FABPL interactions
The ability of in silico computation to hint to the same interactions observed in vitro was veri-
fied by docking the same chemicals to c-FABPL, with and without consensus water. The
computational data are graphically rendered (as Log10Ki) in Fig 7: actually, the list of the
docked chemicals is slightly extended in comparison with the in vitro test as to include a num-
ber of vastatins. Computed Log10Ki range between -2 and -6, with half of the values (20/40)
clustering at -4. Variance between results under different docking conditions appears negligible
(average at -4.51 ± 0.72 in the presence of consensus water, at -4.66 ± 0.84 in the absence of
water) even though, when docking is carried out in the presence of consensus water, the most
frequent interaction of the ligands is with one solvent molecule (52% of the cases as recorded
in PLIF; S4 Fig).
Fig 4. Carbonyl-carboxylic regions of the 13C-NMR spectra of cholic, panel A, and glycocholic acid, panel B, in the presence of c-FABPL. The
spectra of the bile acids in the absence of the protein are shown in traces c and f, respectively. Operating conditions: phosphate buffer pH 7.4, 7 T, 298 K.
doi:10.1371/journal.pone.0132096.g004
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Overall, the in vitro and in silico results point to the ability of c-FABPL to bind a number of
compounds with pharmacological activity and currently used in human therapy. This evidence
suggested extending the investigation to human proteins homologous to the model G. gallus
calycin.
in silico data: human calycin interactions
c-FABPL is homolog to a number of human fatty acid and retinol/retinoic acid binding pro-
teins, with sequence identity between 28 and 43% (not shown). To perform the in silico simula-
tions under the best conditions, from the initial output of 21 entries retrieved from the RCSB
Protein Data Bank, we selected six proteins for which the structure has been resolved in both
the apo and the holo form; they are listed in Table 2 (the entries in order of decreasing similar-
ity to c-FABPL) and their sequence alignment is shown in S1 Fig.
In this protein set, when structure is resolved by X-ray crystallography, calyces of both the
apo and of the holo forms are noticeable for containing a substantial number of water mole-
cules. In a previous investigation on c-FABPL we analyzed the behavior of permanent water
and demonstrated its relevance in the ligand binding process [40]. On this background, as the
first step of the computational part of this work we identified consensus water (S1 Table and
Fig 1), to then dock the test drugs (in Table 1) to the test proteins (in Table 2) both in the pres-
ence and in the absence of these solvent molecules.
The results from the docking procedure are compared with one another and with c-FABPL
in S5 Fig; data for each protein are then grouped in Fig 8.
Log10Ki averaged for each protein across all ligands to provide an easy framework for com-
parison range between -4.5 and -5.4 (with SD between 0.8 and 1.3; not shown). The average
affinities of the human proteins are thus equal to (with h-FABPLH), or higher than (with h-
FABPA, h-FABPE, h-RETI< gastrotropin, h-FABPL), the affinity of c-FABPL for the test
compounds. The proteins whose average affinities most widely diverge from the average affin-
ity of c-FABPL are the ones with closest similarity to it. This evidence suggests that position
and identity of the mutated amino acids may impact on protein function more extensively
than the sheer number of mutations events.
The same data of Fig 8 are then grouped for each ligand in Fig 9; as in the list of Table 1, the
entries are ordered according to their partition coefficient (logP; lower = polar, to
Fig 5. Progressive shift of the resonance of dexamethasone (solid circles) towards the values of the
free ligand (empty circle) on increasing the amount of cholate in solution.Operating conditions:
phosphate buffer pH 7.4, 7 T, 298 K.
doi:10.1371/journal.pone.0132096.g005
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higher = apolar). While there is a trend of the affinity for the test proteins to increase as the
ligands become increasingly hydrophobic (Log10Ki = -0.31 logP - 4.01, for docking with con-
sensus water; Log10Ki = -0.31 logP - 3.96, for docking in the absence of water), the statistical
significance of the correlation is slight (R2 = 0.259 and 0.26, respectively). If the ligands are
sorted on the basis of their structure, the correlation between logP and affinity appears even
lower for vastatins (N = 5; Log10Ki = -0.25 logP—5.06, R
2 = 0.16, with consensus water;
Log10Ki = -0.20 logP - 5.25, R
2 = 0.14, without water) but somewhat higher for steroids (N = 9;
Fig 6. 19F-NMR spectra of the c-FABPL/2-fluoropalmitic complex in the presence of increasing
amounts of cholate (0–20 equivalents).Operating conditions: phosphate buffer pH 7.4, 7 T, 298 K.
doi:10.1371/journal.pone.0132096.g006
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Fig 7. Log10Ki for the interaction of each of the test ligands (in Table 1) with c-FABPL. The holo
structure of the protein (pdb code 1TW4) was taken as receptor and ligand atoms as docking site; the
procedure was repeated in the presence (dark grey bars) and in the absence (light grey bars) of consensus
water (Fig 1 and S1 Table).
doi:10.1371/journal.pone.0132096.g007
Fig 8. Log10Ki for the interaction of all the test ligands (in Table 1) with c-FABPL and the six human
proteins with closest similarity to it (in Table 2; the caption to each data set contains the protein short
name and the pdb code of the test structure). As in Fig 7, docking was repeated in the presence (dark grey
diamonds) and in the absence (light grey squares) of consensus water (S1 Table) except for gastrotropin, for
whose structure only NMR data are currently available.
doi:10.1371/journal.pone.0132096.g008
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Log10Ki = -0.19 logP - 4.54, R
2 = 0.31, with consensus water; Log10Ki = -0.19 logP - 4.65, R
2 =
0.23, without water).
No correlation appears to exist between affinity and topological polar surface area (tPSA)
(Log10Ki = -0.01 tPSA - 4.54, R
2 = 0.0268; Log10Ki = -0.01 tPSA - 4.487, R
2 = 0.04).
For ligands, a single physicochemical parameter is thus insufficient to envisage affinity as
much as a single genetic parameter is for proteins, although polarity seems to play a certain
role.
Indeed, in a summary of highest affinity interactions across all proteins, atorvastatin largely
prevails, with 7/13 instances, followed by cerivastatin (3/13), cholesterol (2/13) and pravastatin
(1/13). Except for the latter, the top-ranking ligands thus correspond to the compounds with
highest logP among vastatins (2 cases) and sterols (1 case).
In order to point out which features in the test calycins are most relevant for affinity to the
test ligands, we obtained PLIF reports for all proteins (S4 Fig) and selected the interactions
occurring in more than 30% of cases (arbitrary cutoff). The list of such items can be read in S2
Table while their rendering is shown in S6 Fig. Color-coding based on protein lets recognize
coincidence in few, seemingly crucial locations.
Discussion
Extensive literature data support the notion that calycins are able to bind a variety of both natu-
ral and synthetic compounds. Among the latter, during focused investigations, interaction has
been demonstrated between selected calycins and selected drugs. The aim of the present inves-
tigation was to test for possible interaction a number of calycins as well as a number of drugs.
This transversal screening had as its starting point a series of in vitro assays on one calycin
Fig 9. Log10Ki for the interaction of each of the test ligands (in Table 1) with the seven test calycins (in
Table 2). Color coding as in Fig 7. Ligand by number as in Table 1.
doi:10.1371/journal.pone.0132096.g009
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purified from natural sources and a panel of drugs with different chemical structure. Occur-
rence of protein-ligand interaction was assessed with a procedure—NMR spectroscopy—fully
adequate to provide the yes/no qualitative response we were looking for at that stage but less
suitable to produce quantitative data on protein-ligand affinity. To carry out the transversal
screening we used instead an in silico approach. This was the only affordable possibility to eval-
uate the interaction between many proteins and many ligands. The procedures of molecular
docking are robust and fully tested in molecular systems similar to those we were investigating.
The specific protocol we actually used in the present investigation was validated as able to
reproduce the spatial setups of a few experimental calycin-ligand structures (S2 Fig). Some of
the in silico data turned out to closely compare with in vitro data obtained by other groups
using different experimental approaches from ours (vide infra).
As detailed under Methods, the in silico protocol included some simplifications. 1. Docking
was to holo forms of all the test calycins, as crystallized with a physiologically relevant natural
ligand. This choice accounts for the overall rearrangement brought about by binding without
fine-tuning it as a function of the ligand till the phase of protein-ligand affinity evaluation. 2.
Docking was performed both in the absence of any water from the calyx and in the presence of
consensus water. The latter were selected among the crystallographic water molecules in each
calycin as the most likely to be relevant in the interaction. While the database of structures
used to recognize such consensus molecules also included for each crystallized protein both the
apo and the holo forms, the possibility that in individual cases the selection includes (one) irrel-
evant or excludes (one) relevant molecule cannot be entirely excluded. 3. Docking was carried
out to mimic a 1:1 interaction stoichiometry. Of the holo forms included in our test panel, two
refer to calycins crystallized with 2 molecules of natural ligand per protein molecule. One more
of them, gastrotropin from various species, is reported to crystallize with 2 molecules of other
natural ligands per protein molecule [42–44]. No summary knowledge about the stoichiometry
of the interaction with calycins is available for the synthetic ligands hence the choice of evaluat-
ing a 1:1 complex may amount to oversimplification but the opposite choice of evaluating 1:2
complexes would imply unverified assumptions. In the experimental 1:2 complexes, binding
affinity appears to be defined in part by the contribution of ligand-ligand interactions and the
affinity varies from one ligand molecule to the other. With our choice we underestimate the
actual affinity not only by systematically cutting to one-half the maximum number of allowed
ligand binding events per protein molecule but also by not taking such ligand-ligand interac-
tions into any account. While this has to be regarded as inaccuracy, in the context of the pres-
ent investigation possibly underestimating affinity is less severe a bias than overestimating it.
Overall, the data presented in this report provide evidence that several synthetic com-
pounds, in clinical use with a variety of indications, are able to bind to intracellular human
calycins with affinities in the same range as their physiological ligands. In the majority of cases
the most favorable interaction of the test proteins is with one of the drugs rather than with a
natural compound (Fig 9 and comments therein).
To verify whether such interactions may possibly have any biological relevance in vivo, we
collected literature data on the pharmacokinetics of the test drugs. Cmax in blood for drugs with
systemic administration are marked in Fig 10 alongside the strongest interactions evaluated by
molecular docking across all the human test calycins.
Cmax is more than two orders of magnitude lower than the highest computed affinity for
dexamethasone given per os and within one order of magnitude lower for simvastatin and ceri-
vastatin. Conversely, peak blood concentration is comparable to the highest evaluated affinity
for the antibacterial norfloxacin, and higher than this threshold for the three antilipemic medi-
cations pravastatin, fluvastatin and atorvastatin.
Lipid-Binding Protein – Drug Interactions
PLOS ONE | DOI:10.1371/journal.pone.0132096 July 13, 2015 15 / 22
While in silico affinity data set a precondition for in vivo interaction, many other factors are
also expected to play a role in the latter through a complex interplay. These include actual
Cmax, depending on the route of administration, as well as tissue distribution, possible depot
effect, binding to other extra- and intra-cellular proteins, competition between exogenous and
endogenous ligands. With all of these provisos the evidence from this investigation can at most
be taken as an indication for a possible in vivo interaction of some drugs with some calycins.
However, we deem this point is worth a notice and, in perspective, a note of caution.
The human genome contains ten FABP genes (five mapping on chromosome 8 and one
each on chromosomes 1, 2, 4, 5, 6) [46]. FABP expression varies across tissues both quantita-
tively (1–5 per cent of cytosolic proteins in hepatocytes, adipocytes and cardiomyocytes vs
lower levels in other less active tissues) and qualitatively (FABP isoforms to serve tissue-specific
functions). Proposed roles for FABPs include assimilation of dietary lipids in the intestine, tar-
geting of liver lipids to catabolic and anabolic pathways, regulation of lipid storage and lipid-
mediated gene expression in adipose tissue and macrophages, fatty acid targeting to β-oxida-
tion pathways in muscle, and maintenance of phospholipid membranes in neural tissues [47].
If it ever occurred, interference with any of these functions would severely impact on homeo-
stasis, from cell to organism level.
The binding properties of various FABPs for xenobiotics have already been not only recog-
nized but indeed exploited by medicinal chemistry, with a few compounds targeting these caly-
cins developed for diagnostic and therapeutic use. Bile acid-conjugated gadolinium chelates
devised as hepatospecific contrast agents in magnetic resonance imaging (MRI) have been
demonstrated to actually bind to c-FABPL [48, 49]. As involved in cytokine production and
cholesterol metabolism, FABPAs are connected with inflammatory and metabolic disorders
[50]; compounds with high affinity for FABPAs and high selectivity against all other FABPs
thus have the potential to prevent or treat diseases such as type-2 diabetes and atherosclerosis
[51–53].
The contribution of FABPLs to intestinal absorption of a number of drugs has been assessed
on the recombinant rat protein using both in vitro and in silico approaches [54]. The set of test
compounds in the reported investigation shares two items with our trial: acetylsalicylic acid
(closely related to fluoroacetylsalicylic) and dexamethasone. For the latter, the experimental Ki
(Ki1 = 22.1 ± 1.5 μM, Ki2 = 41.3 ± 3.7 μM) falls in the range of affinities we have computed for
all human calycins and is very close to the figure we have evaluated for h-FABPL (10.6 μM
with consensus water, 8.5 μMwithout water). For the former, the experimental affinity appears
Fig 10. The highest affinity evaluated with any of the test calycins (Fig 9) is reported for each of the
test drugs in systemic use in comparison with experimental Cmax. Data from http://www.rxlist.com/script/
main/hp.asp and [45].
doi:10.1371/journal.pone.0132096.g010
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Fig 11. Panel A: Holo h-FABPL crystallized to contain two palmitate molecules (pdb code: 3STK). Panel B:
h-FABPL with all the test ligands docked in its cavity.
doi:10.1371/journal.pone.0132096.g011
Lipid-Binding Protein – Drug Interactions
PLOS ONE | DOI:10.1371/journal.pone.0132096 July 13, 2015 17 / 22
to be ca. 20-fold lower than for dexamethasone whereas the computed values differ approxi-
mately 100-fold.
The stoichiometry of high-affinity binding is stated to be 1:1 for all calycins except FABPLs,
irrespective of the species, and for gastrotropin. FABPLs have a large solvent-accessible core (440
Å3) in which binding of two ligand molecules, both like and unlike in structure, has been
reported. NMR (r-FABPL [55, 56]) and crystallography (h-FABPL [57]) provide evidence for
rearrangements occurring in FABPL structure upon binding of the first ligand without further
adjustments upon binding of the second. With two oleate molecules as ligands, a hydrogen bond
between the carboxyl oxygen of the first fatty acid and the side chain NH2 proton of R122 plays a
key role in establishing the first ligand-binding site. The K90 side chain then swivels outward to
create a less crowded and more hydrophobic local environment for the second fatty acid.
The rigid receptor protocol we have used in all the docking procedures does not permit any
movement of the protein parts during the placement steps; rearrangements are instead allowed
to occur during the ligX-optimization step for affinity evaluation. However, since we used as
target the structure of the holo protein, the shape of the calyx was already rearranged and opti-
mized for binding in all parts of the cavity. Affinity of FABPLs for fatty acids scores one-order-
of-magnitude higher with the inward than with the outward ligand (Kd, of h-FABPL for oleic
acid, 0.26 vs 5 μM [57]). Indeed, as shown by Fig 11, the position of all the docked ligands
largely overlaps with that of the inward fatty acid in the crystallized holo structure. This evi-
dence suggests that the estimated affinities are biased, by the inherent approximation of the
procedure, to a similar extent with FABPL (human and chicken) as with any of the other
FABPs. We did not actually assess whether a second molecule of each ligand could be docked
after the first one, and with which affinity. On purely geometrical grounds, binding of a second
molecule seemed possible in all cases.
In addition to the above possible implications in the clinical use of the test drugs, the out-
come of our investigation is a better characterization of the interaction repertoire of intracel-
lular calycins, and the recognition of which amino acids and which (permanent) water
molecules are more often involved in interactions. As for ligands, the apolar character has
been confirmed as one determinant of the affinity, possibly the single most relevant among
manifold factors.
Supporting Information
S1 Fig. Sequence alignment for the selected calycins (http://www.ebi.ac.uk/Tools/msa/
tcoffee/). Color-coding by similarity according to BLOSUM62.
(TIF)
S2 Fig. Validation of the docking protocol. Panel A: Superposition of crystallographic (C
atoms in dark gray) and docked palmitate (C atoms in green) in 2HNX structure. Panel B:
Superposition of crystallographic (C atoms in dark gray) and docked ibuprofen (C atoms in
green) in 6P6G structure. Panel C: Superposition of docked ibuprofen (C atoms in green) in
2HNX structure and crystallographic ibuprofen (C atoms in dark gray) in 6P6G structure, after
alignment of the protein backbones.
(TIF)
S3 Fig. 19F-NMR spectra recorded after the interaction of c-FABPL with 2-fluoropalmitate.
This molecule is insoluble in aqueous buffers and reference data, reported in Table 3, were
obtained in CDCl3. c-FABPL is able to solubilize this molecule: the occurrence of binding is
strongly supported by the longitudinal relaxation time of both the observed resonances, which
is one order of magnitude shorter than the one of the free ligand (0.24 and 0.23 s vs 2.47 s,
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Table 3), and by their negative n.O.e.’s (η = -0.54 and -0.58 vs 0.29, Table 3). Linewidth of the
two signals 25 and 17 Hz, respectively. Operating conditions: PBS, 7 T, 298 K.
(TIF)
S4 Fig. Protein ligand interaction fingerprints weighed via the PLIF procedure on the dock-
ing results for the 20 test ligands (Table 1) on each of the 7 test proteins (Table 2), both in
the presence of consensus water (top panels) and without water (bottom panels). Just the
latter condition applies to gastrotropin, for whose structure only NMR data are currently avail-
able. Water molecules relevant in interactions are boxed.
(TIF)
S5 Fig. Log10Ki for the interaction of each of the test ligands (in Table 1) with c-FABPL and
with the six human proteins with closest similarity to it (listed in Table 2; the caption to
each panel contains the protein short name and the pdb code of the test structure). The
holo structure of each protein was taken as receptor and ligand atoms as docking site; the proce-
dure was repeated in the presence (dark grey bars) and in the absence (light grey bars) of con-
sensus water molecules (Fig 1 and S2 Table).
(TIF)
S6 Fig. Rendering of the items taking interaction with the test ligand in 30% of cases
according to PLIF outputs (S4 Fig; these items are also listed in S2 Table). Color-coding of
the test calycins by chain. The positions, at which a number of interacting amino acids cluster,
correspond to: 16–19 = Phe16 of h-FABPH and of h-FABPA, Phe19 of h-FABPE; 51–
56 = Ser51 of c-FABPL, Ile52 of h-FABPL, Ser53 of h-FABPA, Thr56 of h-FABPE, Thr53 of h-
RETI; 78 = Arg78 of h-FABPH and of h-FABPA; 102–109 = Thr102 of h-FABPL, Arg 106 of
h-FABPH and of h-FABPA, Arg109 of h-FABPE; 120–126 = Arg120 of c-FABPL, Arg122 of h-
FABPL, Arg126 of h-FABPA.
(TIF)
S1 Table. List of consensus water for the 11 calycin structures in Table 2 resolved by X-ray
crystallography.
(DOCX)
S2 Table. Data from PLIF outputs (S4 Fig).
(DOCX)
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